ACTH 1-24
Adrenocorticotropic Hormone 1-24 / Cosyntropin (Tetracosactide)
Evidence & Status
- FDA Approved
- Strong Human Evidence
- Strong
At a Glance
A synthetic ACTH(1-24) fragment used as the diagnostic agent cosyntropin to help evaluate adrenal cortisol response.
Plain English
Cosyntropin is the diagnostic ACTH(1-24) product used to help clinicians assess adrenal response. It is not the same product or evidence base as full-length ACTH(1-39) preparations.
Overview
ACTH 1-24, also called cosyntropin or tetracosactide, is the N-terminal 24-amino-acid fragment of ACTH. This record is limited to CORTROSYN cosyntropin, a diagnostic agent used in screening and evaluation of adrenocortical insufficiency in adults and pediatric patients. It is not a record for full-length ACTH(1-39), HP Acthar Gel, or their therapeutic indications.
Research Summary
CORTROSYN labeling supports cosyntropin (ACTH 1-24) as a diagnostic agent for screening and evaluation of adrenocortical insufficiency, with product-specific IV or IM administration. This evidence framing does not extend to therapeutic use of full-length ACTH(1-39), HP Acthar Gel, or ACTH(1-39)-specific indications.
Research Areas
- Adrenal function
- Adrenocortical insufficiency evaluation
Safety & Risks
Serious Risks
- Hypersensitivity reactions are a labeled safety consideration for CORTROSYN.
Reported Side Effects
- Cortisol elevation (intended effect)
- Fluid retention
- Hypokalemia
- Hypertension
- Hyperglycemia
- Mood changes (euphoria or dysphoria)
- Injection site reactions
Legal Status by Region
- United States
- CORTROSYN (cosyntropin/ACTH 1-24) is a diagnostic agent for evaluation of adrenocortical insufficiency.
- United Kingdom
- Product- and jurisdiction-specific; this record does not assert therapeutic approval.
- Australia
- Product- and jurisdiction-specific; this record does not assert therapeutic approval.
- Canada
- Product- and jurisdiction-specific; this record does not assert therapeutic approval.